Offer Period for Intertrust Offer extended until 19 August 2022
JOINT PRESS RELEASE
This is a joint press release by Intertrust N.V. (“Intertrust” or the “Company”) and CSC (Netherlands) Holdings B.V. (the “Offeror”), pursuant to the provisions of Section 15, paragraph 2 of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft, the “Decree”) in connection with the recommended public offer (the “Offer”) by the Offeror for all the issued and outstanding ordinary shares in the capital of Intertrust. This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities in Intertrust. Any offer will be made only by means of an offer memorandum (the “Offer Memorandum”) approved by the Dutch Authority for Financial Markets (Stichting Autoriteit Financiële Markten, the “AFM”) which has been published on 31 March 2022, and subject to the restrictions set forth therein. With reference to the joint press releases of 6 December 2021 and 31 March 2022, the Offer is subject to the satisfaction or waiver of the Offer Conditions, all in accordance with the terms of the merger agreement (the "Merger Agreement") between Intertrust and the Offeror as executed on 6 December 2021 and the Offer Memorandum. The offer price of EUR 20.00 per Share (the "Offer Price") is "cum dividend". This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, Canada and Japan or any other jurisdiction in which such release, publication or distribution would be unlawful.
Offer Period for Intertrust Offer extended until 19 August 2022
Wilmington, Delaware, USA / Amsterdam, the Netherlands – 30 May 2022 – Reference is made to the joint press release issued by CSC and Intertrust on 31 March 2022 in respect of the publication of the Offer Memorandum for the recommended all-cash public offer by the Offeror for all issued and outstanding shares in the capital of Intertrust at an offer price of EUR 20.00 (cum dividend), on the terms and subject to the conditions and restrictions set forth in the Offer Memorandum.
The offer period ("OfferPeriod") for the Offer has been extended with ten weeks until 19 August 2022, because the time required to obtain the regulatory clearances ("RegulatoryClearances") will extend beyond 10 June 2022, the end of the initial Offer Period.
Intertrust and CSC continue to work constructively to satisfy all other Offer Conditions and are making timely progress. All applications for the Regulatory Clearances have been filed and approval has been obtained from the regulators in Guernsey, Hong Kong and the United Arab Emirates. CSC and Intertrust anticipate that Settlement of the Offer will take place in H2 2022.
As a result of the aforementioned extension of the Offer Period, the Closing Time as referred to in the Offer Memorandum will be changed to 19 August 2022 at 17:40 hours CET.
The extension of the Offer Period is in accordance with and subject to the terms and conditions of the Offer Memorandum, Merger Agreement and Section 15 of the Decree. Shares tendered during the initial Offer Period may be withdrawn during the extended Offer Period in accordance with the terms and conditions of the Offer Memorandum and the provisions of Section 15 paragraph 3 of the Decree. Any shares tendered during the initial Offer Period which are not withdrawn, will remain subject to the Offer.
Regulatory Clearances condition
As set out and described with more detail in the Offer Memorandum, the Offer is subject to Regulatory Clearances having been obtained (without conditions or with conditions accepted by the Offeror pursuant to section 6.8 of the Offer Memorandum (Regulatory Clearances condition)) or the applicable waiting and other time periods (including extensions thereof) under any applicable financial regulatory legislation or regulation having expired, lapsed or terminated in lieu of such authorisation and whereby the Offeror's and Intertrust's counsels agree (acting reasonably and in good faith) that expiry of such waiting and time periods means such Regulatory Clearances are no longer required in order to declare the Offer unconditional.
In the event that the Regulatory Clearances will still not have been obtained by 19 August 2022, the Offeror has agreed in accordance with and subject to the terms of the Merger Agreement to use its reasonable best efforts to apply for an exemption from the AFM to extend the Offer Period again for as long as the Offeror and Intertrust believe to be necessary for all Regulatory Clearances to have been satisfied.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Report – ERYTECH’s Combined Shareholders’ Meeting On June 24, 202224.6.2022 22:05:00 CEST | Press release
REPORT –ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 24, 2022 Cambridge, MA (U.S.) and Lyon (France), June24, 2022 – ERYTECH Pharma (Nasdaq& Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announcedthat its Annual General Meeting was held on Friday, June 24, 2022. At the meeting, all resolutions for which the Board of Directors recommended a vote in favor were adopted, including: Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2021;Allocation of the financial year's results;Approval of the statutory auditors’ special report on regulated agreements and commitments with related parties;Approval of the elements of total compensation and benefits paid or allocated for the year ended December 31, 2021, to Gil BEYEN, Chief Executive Officer and Jean-Paul KRESS, Chairman of the Board;Approval of the compens
Cleantech Building Materials: Results of Annual General Meeting24.6.2022 14:54:27 CEST | Press release
24 June 2022 CLEANTECH BUILDING MATERIALS PLC, NASDAQ FIRST NORTH GROWTH MARKET, COPENHAGEN TICKER: CBM ISIN: GBOOBD1LVD21 CLEANTECH BUILDING MATERIALS PLC Results of Annual General Meeting The Annual General Meeting (“AGM”) of Cleantech Building Materials plc (“CBM” or the “Company”) was held in London earlier today, 24 June 2022. Details of the resolutions to be considered at the AGM were published in the Notice of AGM which was posted to Shareholders on 1 June 2022 and is available on the Company’s website: www.cbm-plc.com. All resolutions as set out in the Notice of AGM were duly passed without discussion. In particular, the following resolutions were passed at the AGM. The AGM resolved to authorise the directors of the Company to allot shares and grant rights to subscribe for, or convert any security, into shares. The directors of the Company sought authority for the purposes of section 551 of the Companies Act to exercise all the powers of the Company to allot shares and grant ri
Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia24.6.2022 13:13:19 CEST | Press release
With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least two prior tyrosine kinase inhibitor treatments1 Positive opinion based on data from pivotal Phase III ASCEMBL trial, showing a near doubling in major molecular response rate for patients treated with Scemblix® (asciminib) vs. Bosulif®* (bosutinib) (25.5% vs. 13.2%) and more than three times lower discontinuation rate due to adverse reactions (5.8% vs 21.1%) at 24 weeks1 CHMP recommendation comes after the approval of Scemblix by the US FDA and other countries’ regulatory authorities, potentially broadening access for more patients to Novartis transformative therapies in CML Basel, June 24, 2022 — Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing au
Clariant’s shareholders approve all agenda items24.6.2022 11:30:00 CEST | Press release
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Integrated Report and Group Consolidated Financial Statements for fiscal year 2021 approvedGünter von Au reelected as Chairman of the Board of DirectorsThree new candidates join the Board of Directors: Ahmed Mohamed Alumar, Roberto César Gualdoni, Naveena ShastriConfirmed distribution of CHF 0.40 per shareKPMG confirmed as statutory auditor from 2022 MUTTENZ, JUNE 24, 2022 Clariant, a focused, sustainable, and innovative specialty chemical company, today held its 27th Annual General Meeting (AGM) where the shareholders approved all agenda items and resolutions as proposed by the Board of Directors. The AGM was held virtually, where shareholders were able to exercise their rights exclusively via the independent proxy. Overall, 698'945'298 shares or around 70.19 % of the share capital of Clariant were represented. Günter von Au was reelected as Chairman of the Board of Directors. Additionally, three new members were voted to join by a large majo
Cool Company Ltd. – Mandatory Notification Of Trade24.6.2022 11:01:19 CEST | Press release
EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 23 June 2022 acquired 7,865 shares in the Company at a price of NOK 90.274882 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,591,218 shares in the Company, equivalent to 38.97% of the Company’s shares. Please see the attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment Primary insider notification form